Optiscan Imaging (OIL) H2 2026 earnings summary

Executive summary

• Transitioned from technology developer to clinical-stage medical device company, focusing on regulatory approval and commercialisation.

• Submitted first FDA regulatory dossier for InSpecta™ and commercially launched it in the U.S. veterinary market.

• Advanced clinical studies for InVue™ and InForm™, generating 152 tissue datasets and progressing toward FDA submissions.

• Strengthened strategic partnerships, notably with Mayo Clinic and Australian Clinical Labs, to support product validation and market entry.

• Raised $17.75 million to accelerate clinical, regulatory, and commercial activities.

Financial highlights

• FY26 revenue was $448,769, down 53% from $951,948 in FY25, mainly due to lower orders from Carl Zeiss Meditec and Viewn Vivo sales.

• Other income rose to $3,711,078 (FY25: $3,106,879), including $2,398,465 in R&D incentives and $766,196 in CRC-P grant payments.

• Total expenses increased to $11,133,244 (FY25: $10,350,445) due to higher R&D and commercial investments.

• Net loss after tax was $6,986,043 (FY25: $6,311,952).

• Net assets increased to $18,944,972 (FY25: $7,712,014), driven by the capital raise.

Outlook and guidance

• Plans to submit FDA dossiers for InVue™ and InForm™ in the next 12 months, supported by ongoing clinical studies.

• Focus on expanding U.S. veterinary market presence for InSpecta™ and advancing next-generation product development.

• Continued emphasis on clinical evidence generation, regulatory readiness, and commercial launch preparation.